• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[肥大细胞增多症与嗜酸性粒细胞白血病:诊断与分类]

[Mastocytosis and eosinophilic leukemia: diagnostics and classification].

作者信息

Sotlar K, Valent P, Horny H-P

机构信息

Pathologisches Institut, Ludwig-Maximilians-Universität München, Thalkirchner Str 36, 80337 München, Deutschland.

出版信息

Pathologe. 2012 Nov;33(6):539-52. doi: 10.1007/s00292-012-1654-0.

DOI:10.1007/s00292-012-1654-0
PMID:23085697
Abstract

Mastocytosis and myeloid eosinophilic neoplasms are rare diseases of the bone marrow and are often a diagnostic challenge for hematopathologists. In mastocytosis, compact mast cell infiltrates represent the main diagnostic criterion and for myeloid eosinophilic neoplasms, eosinophilic granulocytes dominate the histological picture. Both disease groups include phenotypically and prognostically very different entities which are each defined by WHO criteria. For systemic mastocytosis (SM), a differentiation between indolent and aggressive or even leukemic forms is of prognostic importance. In indolent variants of SM, a local and/or systemic, usually reactive increase in eosinophilic granulocytes (SM-eo) is often observed. In contrast, an increase in neoplastic eosinophils is often observed in advanced SM, predominantly in diseases designated SM with associated non-mastocytic hematological neoplasms (SM-AHNMD), e.g. in SM with chronic eosinophilic leukemia (SM-CEL). Apart from mastocytoses, immunophenotypically aberrant tissue mast cells are only observed in certain rare forms of myeloid neoplasms with eosinophilia, in particular in myeloproliferative neoplasms (MPN-eo) with cytogenic anomalies in the platelet-derived growth factor receptor (PDGFR). The World Health Organization (WHO) classification of eosinophilic leukemias, however, fulfils the morphological and clinical requirements in a limited way only and needs an update.

摘要

肥大细胞增多症和髓系嗜酸性粒细胞肿瘤是罕见的骨髓疾病,对血液病理学家来说常常是诊断上的挑战。在肥大细胞增多症中,致密的肥大细胞浸润是主要诊断标准,而在髓系嗜酸性粒细胞肿瘤中,嗜酸性粒细胞在组织学图像中占主导。这两个疾病组都包括表型和预后差异很大的实体,每个实体都由世界卫生组织(WHO)标准定义。对于系统性肥大细胞增多症(SM),区分惰性和侵袭性甚至白血病形式具有预后重要性。在SM的惰性变体中,通常会观察到嗜酸性粒细胞局部和/或全身的、通常为反应性的增加(SM-eo)。相反,在晚期SM中,尤其是在伴有非肥大细胞性血液肿瘤的SM(SM-AHNMD),例如伴有慢性嗜酸性粒细胞白血病的SM(SM-CEL)中,常观察到肿瘤性嗜酸性粒细胞增多。除了肥大细胞增多症外,免疫表型异常的组织肥大细胞仅在某些罕见的伴有嗜酸性粒细胞增多的髓系肿瘤中观察到,特别是在血小板衍生生长因子受体(PDGFR)有细胞遗传学异常的骨髓增殖性肿瘤(MPN-eo)中。然而,世界卫生组织(WHO)对嗜酸性粒细胞白血病的分类仅在有限程度上满足形态学和临床要求,需要更新。

相似文献

1
[Mastocytosis and eosinophilic leukemia: diagnostics and classification].[肥大细胞增多症与嗜酸性粒细胞白血病:诊断与分类]
Pathologe. 2012 Nov;33(6):539-52. doi: 10.1007/s00292-012-1654-0.
2
Mastocytosis: state of the art.肥大细胞增多症:最新进展
Pathobiology. 2007;74(2):121-32. doi: 10.1159/000101711.
3
Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review.系统性肥大细胞增多症在常规处理的骨髓活检标本中的鉴别诊断:综述。
Pathobiology. 2010;77(4):169-80. doi: 10.1159/000305552. Epub 2010 Jul 7.
4
Diagnostic criteria and classification of mastocytosis: a consensus proposal.肥大细胞增多症的诊断标准与分类:一项共识提议。
Leuk Res. 2001 Jul;25(7):603-25. doi: 10.1016/s0145-2126(01)00038-8.
5
Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis.髓系肥大细胞重叠综合征:生物学、诊断标准及与肥大细胞增多症的关系
Leuk Res. 2001 Jul;25(7):595-602. doi: 10.1016/s0145-2126(01)00040-6.
6
Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.系统性肥大细胞增多症中骨髓组织学集中评估的影响
Eur J Clin Invest. 2016 May;46(5):392-7. doi: 10.1111/eci.12607. Epub 2016 Mar 21.
7
Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.与慢性嗜酸性粒细胞白血病相关的系统性肥大细胞增多症(SM-CEL):FIP1L1/PDGFRα的检测、按世界卫生组织标准分类以及对伊马替尼治疗的反应
Leuk Res. 2006 Sep;30(9):1201-5. doi: 10.1016/j.leukres.2005.11.014. Epub 2006 Jan 6.
8
Systemic mastocytosis: progressive evolution of an occult disease into fatal mast cell leukemia: unique findings on an unusual hematological neoplasm.系统性肥大细胞增生症:隐匿性疾病向致命性肥大细胞白血病的进展:一种不常见血液肿瘤的独特表现。
Med Oncol. 2012 Dec;29(5):3540-6. doi: 10.1007/s12032-012-0261-5. Epub 2012 Jun 3.
9
The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD).系统性肥大细胞增多症的分类应包括肥大细胞白血病(MCL)和伴有克隆性血液学非肥大细胞谱系疾病的系统性肥大细胞增多症(SM-AHNMD)。
Blood. 2010 Aug 5;116(5):850-1. doi: 10.1182/blood-2010-05-285270.
10
Proposal for a revised classification of systemic mastocytosis.关于系统性肥大细胞增多症修订分类的提议。
Blood. 2010 Apr 1;115(13):2720-1. doi: 10.1182/blood-2009-12-259085.

本文引用的文献

1
Evaluation of mast cell activation syndromes: impact of pathology and immunohistology.肥大细胞激活综合征的评估:病理学和免疫组织化学的影响。
Int Arch Allergy Immunol. 2012;159(1):1-5. doi: 10.1159/000336374. Epub 2012 Apr 27.
2
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.当代关于嗜酸性粒细胞疾病和相关综合征的标准和分类的共识建议。
J Allergy Clin Immunol. 2012 Sep;130(3):607-612.e9. doi: 10.1016/j.jaci.2012.02.019. Epub 2012 Mar 28.
3
Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis.
高等级肥大细胞病中肿瘤性肥大细胞 CD30 的异常表达。
Mod Pathol. 2011 Apr;24(4):585-95. doi: 10.1038/modpathol.2010.224. Epub 2010 Dec 24.
4
Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review.系统性肥大细胞增多症在常规处理的骨髓活检标本中的鉴别诊断:综述。
Pathobiology. 2010;77(4):169-80. doi: 10.1159/000305552. Epub 2010 Jul 7.
5
Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD).与系统性肥大细胞增多症(SM-AHNMD)相关的克隆性血液非肥大细胞谱系疾病中 KITD816V 的可变存在。
J Pathol. 2010 Apr;220(5):586-95. doi: 10.1002/path.2677.
6
Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.与慢性特发性骨髓纤维化相关的系统性肥大细胞增多症:系统性肥大细胞增多症的一种独特亚型,与一种携带激活点突变KIT D816V和JAK2 V617F的克隆性血液非肥大细胞谱系疾病相关。 (注:原文中“[corrected]”表示此处可能是修正后的内容,翻译时保留原样。)
J Mol Diagn. 2008 Jan;10(1):58-66. doi: 10.2353/jmoldx.2008.070061. Epub 2007 Dec 28.
7
Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria.肥大细胞增多症的标准与标准化:关于诊断、治疗建议及反应标准的共识声明
Eur J Clin Invest. 2007 Jun;37(6):435-53. doi: 10.1111/j.1365-2362.2007.01807.x.
8
The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markers.骨髓中类胰蛋白酶阳性致密圆形细胞浸润(TROCI-BM):一种需要应用谱系特异性标志物的新型组织病理学发现。
J Clin Pathol. 2006 Mar;59(3):298-302. doi: 10.1136/jcp.2005.028738.
9
Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia.系统性肥大细胞增多症中骨髓肥大细胞浸润模式的描绘:CD25的价值、与疾病亚型的相关性以及与肥大细胞增生的鉴别
Am J Clin Pathol. 2005 Oct;124(4):560-8. doi: 10.1309/CX45R79PCU9HCV6V.
10
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.t(8;9)(p22;p24)是慢性和急性白血病中的一种复发性异常,它使PCM1与JAK2融合。
Cancer Res. 2005 Apr 1;65(7):2662-7. doi: 10.1158/0008-5472.CAN-04-4263.